The reasons are presumably multifactorial and may include loss of tumor antigen expression or alterations in antigen presentation capacities and upregulation of immuno-suppressive surface molecules or other suppressive mediators leading to immune cell exhaustion, resulting in anti–PD-1 resistance and IL2 unresponsiveness. Here, IL2 is linked to neoplasm.